American Society of Hematology

Figure 6.

$Figure 6. ICSBP overrides imatinib resistance in BCR/ABL-transformed 32D cells. ICSBP+ and ICSBP-cell lines were treated with 1 μM imatinib for 48 hours and subsequently stained with annexin V-FITC and PI. (A) The percentage of dead cells, defined as either annexin+/PI- (apoptotic) or annexin+/PI+ (necrotic) is indicated in the upper right quadrant of each plot. The percentage of live cells is indicated in the lower left quadrant. (B) Because of expression of GFP (Mig-p210) in 32D/BA-ICSBP on/off cells, the percentage of dead cells was calculated solely from the PI+ fraction, which is outlined in the upper left quadrant of each dot plot. The difference in the apoptosis rates of each pair of ICSBP+ and ICSBP-cell lines was statistically significant as indicated (P < .001 and P < .01 for stable and inducible ICSBP-expressing cell systems, respectively).$

ICSBP overrides imatinib resistance in BCR/ABL-transformed 32D cells. ICSBP⁺ and ICSBP-cell lines were treated with 1 μM imatinib for 48 hours and subsequently stained with annexin V-FITC and PI. (A) The percentage of dead cells, defined as either annexin⁺/PI^- (apoptotic) or annexin+/PI⁺ (necrotic) is indicated in the upper right quadrant of each plot. The percentage of live cells is indicated in the lower left quadrant. (B) Because of expression of GFP (Mig-p210) in 32D/BA-ICSBP on/off cells, the percentage of dead cells was calculated solely from the PI⁺ fraction, which is outlined in the upper left quadrant of each dot plot. The difference in the apoptosis rates of each pair of ICSBP⁺ and ICSBP-cell lines was statistically significant as indicated (P < .001 and P < .01 for stable and inducible ICSBP-expressing cell systems, respectively).

This Feature Is Available To Subscribers Only